Keyphrases
Non-small Cell Lung Cancer (NSCLC)
100%
Liver Metastasis
100%
Economic Outcomes
100%
Bevacizumab
100%
Real-world Clinical Outcomes
100%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
44%
Survival Benefit
22%
Poor Survival
22%
Healthcare Resource Utilization
22%
High Cost
22%
Hazard Ratio
22%
Hospitalization
11%
Patient Demographics
11%
Treatment Effect
11%
Improved Outcomes
11%
Overall Survival
11%
Fold Increase
11%
Vasculature
11%
Improved Survival
11%
Electronic Health Records
11%
Poor Outcome
11%
Median Overall Survival
11%
Multivariable
11%
Baseline Characteristics
11%
Length of Stay
11%
Electronic Health Record Databases
11%
Cox Proportional Hazards Regression Model
11%
Real-world Clinical Data
11%
Claims Database
11%
Survival Median
11%
Retrospective Cohort Analysis
11%
Inpatient Costs
11%
Cost Difference
11%
Relative Survival
11%
Economic Data
11%
Liver Microenvironment
11%
Antiangiogenesis Inhibitors
11%
Medicine and Dentistry
Liver Metastasis
100%
Non Small Cell Lung Cancer
100%
Bevacizumab
100%
Health Care Cost
55%
Overall Survival
22%
Electronic Health Record
22%
Hazard Ratio
22%
Health Care
22%
Cohort Analysis
11%
Proportional Hazards Model
11%
Antiangiogenic Activity
11%
Vascularity
11%
Relative Survival
11%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Liver Metastasis
100%
Bevacizumab
100%
Overall Survival
22%
Immunology and Microbiology
Bevacizumab
100%
Overall Survival
33%
Electronic Health Record
33%
Vascularization
16%
Antiangiogenic Activity
16%